2024
Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI
Abu-Much A, Grines C, Chen S, Batchelor W, Zhao D, Falah B, Maini A, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Zhang Y, Zhou Z, Baron S, Lansky A, Basir M, O'Neill W, Cohen D. Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI. International Journal Of Cardiology 2024, 417: 132555. PMID: 39270940, DOI: 10.1016/j.ijcard.2024.132555.Peer-Reviewed Original ResearchLower left ventricular ejection fractionMitral valve regurgitationPercutaneous coronary interventionHigh-risk PCISevere MRHigh-risk percutaneous coronary interventionMR severityPCI-related complicationsValve regurgitationIII studiesHeart failureAssociated with worse outcomesPrevalence of heart failurePresence of severe MRLower body mass indexVentricular ejection fractionStatistical significanceHigh-risk PCI patientsBody mass indexTrace MREjection fractionModerate MRClinical outcomesMild MRWorse outcomesMechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weight
2023
Impact of Steroid Withdrawal on Gene Expression Profiling, Donor Derived Cell-Free DNA, and Clinical Outcomes in the SHORE Registry
Bellumkonda L, Uriel N, Fu Y, Shen L, Qu K, Baran D. Impact of Steroid Withdrawal on Gene Expression Profiling, Donor Derived Cell-Free DNA, and Clinical Outcomes in the SHORE Registry. The Journal Of Heart And Lung Transplantation 2023, 42: s494. DOI: 10.1016/j.healun.2023.02.1362.Peer-Reviewed Original ResearchDe novo donor-specific antibodiesDd-cfDNA levelsCardiac allograft vasculopathySteroid withdrawalGraft dysfunctionCell-free DNAGEP scoreGene expression profilingMulti-organ transplant recipientsNovo donor-specific antibodiesDe novo DSAPost-heart transplantSteroid withdrawal groupDonor-specific antibodiesAllograft vasculopathySteroid doseCause mortalityTransplant recipientsMethods PatientsSteroid treatmentComplete discontinuationPropensity matchingClinical outcomesOutcomes RegistryWithdrawal group